Yamakawa Midori, Liu Louis X, Date Taro, Belanger Adam J, Vincent Karen A, Akita Geoffrey Y, Kuriyama Takayuki, Cheng Seng H, Gregory Richard J, Jiang Canwen
Genzyme Corporation, 31 New York Ave, Framingham, Mass 01701-9322, USA.
Circ Res. 2003 Oct 3;93(7):664-73. doi: 10.1161/01.RES.0000093984.48643.D7. Epub 2003 Sep 4.
Hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of vascular endothelial growth factor (VEGF) and other hypoxia-responsive genes. Transgenic expression of a constitutively stable HIF-1alpha mutant increases the number of vascular vessels without vascular leakage, tissue edema, or inflammation. This study aimed to investigate the molecular basis by which HIF-1 mediates the angiogenic response to hypoxia. In primary human endothelial cells, hypoxia, desferrioxamine, or infection with Ad2/HIF-1alpha/VP16, an adenoviral vector encoding a constitutively stable hybrid form of HIF-1alpha, increased the mRNA and protein levels of VEGF, angiopoietin-2 (Ang-2), and angiopoietin-4 (Ang-4). Infection with Ad2/CMVEV (a control vector expressing no transgene) had no effect. Angiopoietin-1 (Ang-1) expression was not detected in human endothelial cells. Ang-4 was also induced by hypoxia or Ad2/HIF-1alpha/VP16 in human cardiac cells, whereas Ang-1 expression remained unchanged. Recombinant Ang-4 protein protected endothelial cells against serum starvation-induced apoptosis and increased cultured endothelial cell migration and tube formation. Ad2/HIF-1alpha/VP16 stimulated endothelial cell proliferation and tube formation. Hypoxia- or Ad2/HIF-1alpha/VP16-induced tube formation was significantly reduced by a Tie-2 inhibitor. These results suggest that HIF-1 mediates the angiogenic response to hypoxia by upregulating the expression of multiple angiogenic factors. Ang-4 can function similarly as Ang-1 and substitute for Ang-1 to participate in hypoxia-induced angiogenesis. Activation of the angiopoietin/Tie-2 system may play a role in the ability of HIF-1 to induce hypervascularity without excessive permeability.
Biochem Biophys Res Commun. 2002-3-8
Br J Pharmacol. 2002-11
N Engl J Med. 2000-3-2
Ann Med Surg (Lond). 2025-5-29
Front Endocrinol (Lausanne). 2025-7-17
J Mol Med (Berl). 2025-5-30
J Clin Med. 2024-12-19